Literature DB >> 1359206

Medical therapy for ocular allergy.

S D Trocme1, M B Raizman, G B Bartley.   

Abstract

The ocular manifestations of allergy have traditionally been classified into four categories--namely, hay fever conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, and contact lens-associated giant papillary conjunctivitis. Typically, hay fever conjunctivitis is characterized by mild conjunctival inflammation, whereas the other disorders may have severe inflammation and clinical manifestations. Potentially blinding corneal complications may result from vernal keratoconjunctivitis and atopic keratoconjunctivitis. Although hay fever conjunctivitis is clearly an immediate hypersensitivity reaction, the immunologic mechanisms that cause vernal keratoconjunctivitis, atopic keratoconjunctivitis, and giant papillary conjunctivitis are primarily unknown and speculative. Treatment of patients with ocular allergies is often challenging and may necessitate collaborative efforts of an ophthalmologist and an allergist. Herein we discuss conventional therapy and new, promising antiallergy drugs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1359206     DOI: 10.1016/s0025-6196(12)60464-9

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  5 in total

1.  Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety.

Authors:  Veysi Oner; Fatih Mehmet Türkcü; Mehmet Taş; Mehmet Fuat Alakuş; Yalçın Işcan
Journal:  Jpn J Ophthalmol       Date:  2012-05-25       Impact factor: 2.447

Review 2.  [Ocular allergies].

Authors:  E M Messmer
Journal:  Ophthalmologe       Date:  2005-05       Impact factor: 1.059

3.  Levocabastine eye drops in the treatment of vernal conjunctivitis.

Authors:  F Goes; S Blockhuys; M Janssens
Journal:  Doc Ophthalmol       Date:  1994       Impact factor: 2.379

4.  [Atopic keratoconjunctivitis: probably a risk factor for the development of conjuntival carcinoma].

Authors:  C Kallen; T Reinhard; G Schilgen; O Cartsburg; A Böcking; C Auw-Hädrich; R Sundmacher
Journal:  Ophthalmologe       Date:  2003-10       Impact factor: 1.059

5.  Exacerbation of signs and symptoms of allergic conjunctivitis by a controlled adverse environment challenge in subjects with a history of dry eye and ocular allergy.

Authors:  Paulo J Gomes; George W Ousler; Donna L Welch; Lisa M Smith; Jeffrey Coderre; Mark B Abelson
Journal:  Clin Ophthalmol       Date:  2013-01-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.